National Institute of Allergy and
Infectious Diseases (NIAID)
http://www.niaid.nih.gov
Infectious Diseases (NIAID)
http://www.niaid.nih.gov
FOR IMMEDIATE RELEASE
Wednesday, Oct. 30, 2013
Wednesday, Oct. 30, 2013
MEDIA AVAILABILITY
HIV Antibody Infusions Show Promise for Treating SHIV-Infected Monkeys
HIV Antibody Infusions Show Promise for Treating SHIV-Infected Monkeys
NIH-Supported Scientists Advocate Trying Similar Strategy in People
In the study led by NIAID grantees, the antibody infusions reduced SHIV viral load to an undetectable level in 16 of 18 monkeys within just 7 days and kept it there for a median of 56 days, when the infused antibodies were gone. While the two monkeys with the highest viral loads at the outset of the study never achieved undetectable viral loads, the three monkeys with the lowest viral loads at the outset maintained stable, undetectable viral loads long after the infused antibodies were gone. The antibody infusions appeared both to improve the monkeys’ control of the virus and to reduce the presence of SHIV DNA in blood and tissues without generating SHIV resistance to the antibodies.
In the study led by NIAID scientists, infusion of a single antibody to 4 monkeys infected for 3 months quickly reduced SHIV viral load to undetectable levels for 4 to 7 days, but then virus reappeared and strains in two animals were antibody-resistant. Yet when two asymptomatic monkeys SHIV-infected for more than 3 years received an infusion of two antibodies, viral load fell to undetectable levels within 7 to 10 days and remained there for 18 to 36 days. A second infusion reduced viral load to undetectable levels for 4 to 28 days. When virus reappeared, strains in one monkey were antibody-resistant. Infusion of the same antibody pair into three monkeys SHIV-infected for more than 3 years and with AIDS symptoms provided modest or no benefit but did not generate resistance.
The studies’ authors now propose testing antibody-based immunotherapy in HIV-infected people and exploring the potential role of antibody infusions in curing people of HIV.
ARTICLES:DH Barouch et al. Therapeutic efficacy of potent neutralizing HIV-1 specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature DOI: 10.1038/nature12744 (2013).
M Shingai et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viremia. Nature DOI: 10.1038/nature12746 (2013).
WHO:NIAID Director Anthony S. Fauci, M.D., and Distinguished NIH Senior Investigator Malcolm A. Martin, M.D., are available for comment.
CONTACT:To schedule interviews, please contact Laura S. Leifman, (301) 402-1663, laura.sivitz@nih.gov.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH...Turning Discovery Into Health ®
No hay comentarios:
Publicar un comentario